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ABSTRACT
Aim: The main treatment for meibomian gland
dysfunction (MGD), a major cause of dry eye, is
eyelid warming. Lack of compliance is the main
reason for treatment failure. This has led to the
development of eyelid-warming devices that are
safe, effective and convenient. To obtain robust
evidence demonstrating their efficacy, the
authors conducted a 3-arm randomized
clinical study.
Methods: The authors conducted a 3-month
assessor-blinded, randomized, controlled trial of
patients from the Singapore National Eye
Centre experiencing at least one of eight dry
eye symptoms ‘often’ or ‘all the time’. Patients
who wore contact lenses, had an active
infection or known diagnosis of thyroid
dysfunction and rheumatoid arthritis were
excluded from the study. MGD participants
were randomly assigned to warm towel
(n = 25), EyeGiene (Eyedetec Medical Inc.,
Danville, CA, USA) (n = 25) and Blephasteam
(Spectrum Thea Pharmaceuticals LTD,
Macclesfield, UK) (n = 25) treatments. The
primary efficacy and safety outcomes included
the proportions of participants with improved
symptoms and changes in best corrected visual
acuity (BCVA), respectively. Other outcomes
included tear break up time (TBUT), Schirmer
test, corneal fluorescein dye staining and
number of visibly occluded meibomian gland
(MG) orifices.
Results: The study population was
53.5 ± 11.1 years old and predominantly
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Chinese. For severity of symptom after
3 months of treatment, 78.3% Blephasteam
participants reported improvement compared
to 45.5% warm towel participants (p = 0.023).
The corresponding proportions for
improvement in the frequency of symptoms
were 82.6% and 50.0%, respectively (p = 0.020).
The proportions of improvement of symptoms
in EyeGiene patients were not significantly
different from warm towel intervention. At
1 month of treatment, the crude odds ratio of
improvement of severity of irritation for
Blephasteam compared to control was 3.0
(95% CI 0.88–10.18). However, the odds ratio
adjusted by age was 5.67 (1.30–24.66). The
lid-warming treatments did not significantly
change the TBUT, Schirmer test results or
number of visibly occluded MGs in the study
period. All treatment modalities did not worsen
BCVA after 3 months.
Conclusion: Blephasteam is more effective
than warm towel for MGD treatment, with
warm towel and EyeGiene being comparable
effective. Older age might predict for treatment
efficacy. All studied therapies were safe for
visual acuity (VA) for 3 months of treatment.
Keywords: Blephasteam; Clinical study; Dry
eye; EyeGiene; Human; Longitudinal study;
Meibomian gland dysfunction; Randomized
controlled trial; Ophthalmology; Warm
compress
INTRODUCTION
Dry eye is a common condition with symptoms
that impact patients’ quality of life [1, 2]. It is
perceived to be as distressing as chest pain [3]
and imposes considerable healthcare costs, up
to US$1.1 million per 1,000 persons annually
[4], and productivity costs [1]. Meibomian gland
dysfunction (MGD) is a chronic abnormality of
the meibomian glands (MGs) [5]. It may cause
eye discomfort [6] and affect tear film stability
[5] which leads to poorer visual function, faster
tear evaporation and ocular surface damage [7].
MGD is thought to be a major cause of dry eye
that affects 46.2–69.3% Asians and 3.5–19.9%
Caucasians [8–10].
The cornerstone therapy for MGD is warm
compress [11]. Various forms of eyelid-warming
therapy have been shown to improve patients’
symptoms [12–19], tear film stability [12–18],
slow down tear evaporation [14] and reduce
ocular surface damage [18, 20]. Other additional
treatments such as lubricating drops,
antibiotics, anti-inflammatory cyclosporine
and topical azithromycin are prescribed for
more severe MGD [11].
The recommended regimen for warm
compress is daily treatment [11]. This is prone
to poor compliance and difficulty in delivering
therapeutic temperatures [21]. Several eyelid-
warming devices with features that improve
convenience and deliver heat at safe, calibrated
temperatures to the eyelids have been
developed recently [15, 22]. Two examples are
EyeGiene (Eyedetec Medical Inc., Danville,
CA, USA) and Blephasteam (Spectrum Thea
Pharmaceuticals LTD, Macclesfield, UK).
EyeGiene is a compact system composed of
an eye mask and sachets containing heat-
generating chemicals. Blephasteam is a
portable pair of goggles which uses moist heat
instead of physical contact for heat transfer to
the eyelids.
However, little evidence exists on the
effectiveness, especially in long-term use, of
these eyelid-warming devices. Current reports
on EyeGiene [14, 16] and Blephasteam
[17–20, 22] do not have control groups for
comparison and all except one abstract [16]
show effects of short-term (up to 3 weeks)
38 Ophthalmol Ther (2014) 3:37–48
studies, or after just one application of the
device. Two articles [20, 22] also reported effects
in healthy as opposed to MGD participants.
The aim of this study was to evaluate the
effectiveness and safety of EyeGiene and
Blephasteam against the conventional warm
towel compress in a randomized controlled trial
involving MGD patients.
METHODS
Study Design and Participants
This is a 3-month randomized, controlled
trial comparing two eyelid-warming devices,
EyeGiene and Blephasteam, and warm towel
compress in MGD participants.
From February 2012 to October 2013, all
patients at the Singapore National Eye Centre
dry eye clinic who met the eligibility criteria
were briefed about this study and invited for
screening. The MGD in this study is not
classified into severity levels but as long as the
morphological eligibility criterion below and
specified symptoms are present, they can be
included. Eligible participants were then
enrolled with written informed consent by the
clinical trial coordinator.
Compliance with Ethics Guidelines
The study has been approved by the SingHealth
Centralized Institutional Review Board and
adhered to the tenets of the Declaration of
Helsinki of 1975, as revised in 2000 and 2008.
Eligibility
These patients were included for the study:
• At least one of eight dry eye symptoms
(Supplementary Fig. 1—questionnaire
modified after Schein et al. [23]) was
experienced ‘‘often’’ or ‘‘all the time.’’
• At least one MG opening with pouting and a
visible plug above the eyelid margin that
cannot be removed by gentle wiping with a
cotton tip.
• No ocular pathology requiring treatment
other than eye lubricant and conventional
eyelid hygiene within the last month and
during the study.
• Participants with data at baseline and
1 month after treatment.
These patients were excluded from the study:
• Known diagnosis of thyroid dysfunction and
rheumatoid arthritis.
• Ocular surgery within the previous 6 months
and laser-assisted in situ keratomileusis
(LASIK) within the previous year.
• Central nervous system and hormonal drugs
required within the last month and during
the study.
• Active ocular infection or presence of
pterygium.
• Necessity to wear contact lens during the
study.
• Living in the same household as another
participant of the study.
Randomization and Blinding
The nursing manager and two witnesses drew
lots to determine the random allocation
sequence of participants to the three treatment
methods in a 1:1:1 ratio. The assessor of the
participants’ clinical signs was blinded to the
treatment method of each participant.
Interventions
All participants were required to self-administer
the eyelid-warming therapies twice daily, for
10 min each time, then briefly massage their
eyes and clean their eyelids with Blephagel
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(Spectrum Thea Pharmaceuticals LTD,
Macclesfield, UK) and cotton pads.
Control Arm
Participants were given a towel to warm in
warm water before placing it over their eyes.
They were instructed to re-warm the towel
when they feel it get cooler.
EyeGiene
The manufacturer claims that when the
chemicals in the disposable sachets are mixed
together and placed in the pockets of the eye
mask, they deliver 40 C heat to the eyelids for
8–10 min. The clinical trial coordinator would
demonstrate how to activate the warming unit
and use the eye mask as well as watch the
participant activating one warming unit.
Blephasteam
The Blephasteam goggles are electrically
powered and have to be preheated for 15 min.
New Blephasteam rings were moistened and
fitted in the goggles before each 10-min session.
Printed instructions from Blephasteam were
provided to each Blephasteam participant.
Compliance Measures and Concurrent
Medications
The participants were given a diary to record
details of each treatment session (time and
duration), eyelid cleaning with Blephagel and
use of eye lubricant. Participants were allowed to
use eye lubricants but not antibiotics, steroid and
anti-inflammatory eye drops such as cyclosporine
as stipulated in the inclusion criteria.
Efficacy Outcome Measures
The primary efficacy outcome was the
proportion of participants with improvement
in severity and frequency of eye discomfort after
1 month of treatment. The secondary efficacy
outcomes were the proportions of participants
with improvement in symptom severity
and frequency between 1 and 3 months
of treatment. The symptom severity and
frequency were performed on a visual analog
scale as previously described [24]. The details of
all the study procedures are provided in the
supplementary file.
Safety Outcome
Adverse events (AEs) and serious adverse events
(SAEs) were monitored but the pre-specified
safety outcome was changed in VA after
3 months of treatment. This is because a
previous study found VA to be affected by lid
warming [25].
Exploratory Efficacy Outcomes
Our exploratory outcomes were the changes in
TBUT, number of plugged MG openings,
corneal fluorescein staining and Schirmer’s test
after 1 and 3 months of treatment.
Statistical Analyses
Sample Size Calculation
There was little literature on the magnitude of
symptom change on this scale that would be
clinically significant. Based on clinical
assumption, and taking into account the cost
of the eyelid-warming devices, the authors
endeavored to detect a 40% difference in
proportion of participants with the primary
outcome of improved symptom severity/
frequency between the EyeGiene/
Blephasteam and the warm towel groups
after 1 month of treatment. Conservatively,
the proportion of warm towel participants (the
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current practice) with improved severity/
frequency was assumed to be 40%. Hence, 22
participants in each study arm were required for
80% power and a two-sided significance level of
5%. Therefore, the aim was to recruit 25
participants per arm to allow for three losses
to follow-up or withdrawals per arm.
Statistical Analyses
Data were checked for normality to determine
the appropriate parametric or non-parametric
test. To test for differences among groups,
relevant Chi square test, one-way analysis of
variance (ANOVA) and Kruskal–Wallis equality-
of-populations rank test were used. Where there
was difference among groups, the authors
performed the relevant Student’s t test or
Wilcoxon rank sum test. Chi square test was
used to evaluate the differences in the primary
and secondary outcomes between groups.
Logistic regression was used to adjust for
baseline differences. The analysis was by
intention to treat. Statistically significant
difference was based on 0.05 level of
significance. All analyses were performed with
Stata software, version 12.1 (StataCorp. College
Station, TX, USA).
RESULTS
Of 102 patients who were assessed for eligibility,
75 were enrolled. Subsequently three patients
were found to have a history of thyroid disease
and were therefore considered not eligible. The
other 72 patients were randomized into three
equal groups (Supplementary Fig. 2). Table 1
shows the patients (n = 65) who were
successfully followed up and had data at
1 month (primary outcome analysis). The ages
of these participants were 53.5 ± 11.1 years,
with 67.7% female (Table 1) and
predominantly Chinese (exceptions are 2
Malay patients, 2 Indian patients and 1
Burmese patient). There were no comorbidities
in any group.
Then MGD grading was similar in all the
groups studied. The mean number of blocked
glands in each of the groups was not
significantly different (Table 1). Baseline
severity of eye discomfort was significantly less
in EyeGiene (23.6 ± 14.9) compared to the
other two groups (p = 0.0008) (Table 1). Corneal
staining was significantly less severe in the
Blephasteam group (p = 0.030; Table 1). All
other baseline characteristics were not
significantly different among the three groups.
Overall, the mean TBUT ± SD was 2.4 s ± 1.4
and the Schirmer I was 11.7 mm ± 10.4 at
baseline.
There were eight withdrawals from the
EyeGiene group before the assessment at the
1-month time point. These cases had more
severe and frequent eye discomfort and higher
Schirmer I readings compared to the remaining
EyeGiene participants. The reason for
withdrawal was the inability to activate the
EyeGiene warming units. The problem was not
resolved with additional counseling; the
manufacturers would improve the device in
future batches (personal communication).
Because the number of patients on EyeGiene
for analysis was less than the calculated number
required, we recruited another seven patients
(non-randomized) who were treated with
EyeGiene for an additional analysis and
performed a two group analysis comparing
this treatment with warm towels
(Supplementary Tables 2, 3). Essentially the
conclusions concerning the efficacy outcomes
comparing the augmented EyeGiene group
versus the original towel groups are the same
as that presented below.
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The proportions of participants with
reduced frequency of eye discomfort after
1 month of treatment (primary efficacy
outcome) were 54.2% for warm towel, 52.9%
EyeGiene and 79.2% for Blephasteam
(Table 2). The proportions with reduced
severity at 1 month were 50.0%, 52.9% and
75.0%, respectively. There were no significant
Table 1 Baseline characteristics of study groups
Towel EyeGiene Blephasteam P value
Number of participants 24 17 24
Female participants
No. (%) 19 (79.2) 10 (58.8) 15 (62.5) 0.308
Chinese participants
No. (%) 23 (95.8) 16 (94.1) 21 (87.5) 0.841
Age/years
Mean ± SD 56.3 ± 11.0 53.1 ± 9.4 50.9 ± 12.0 0.239
Symptom Severity score, mm
Mean ± SD 52.8 ± 21.4 23.6 ± 14.9 41.4 ± 28.3 0.0008*
Symptom Frequency score, mm
Mean ± SD 51.9 ± 18.7 30.7 ± 26.8 40.8 ± 25.1 0.247
TBUT/s
Median (interquartile range) 1.9 (1.5–2.5) 2.3 (1.5–3.0) 1.8 (1.4–3.0) 0.482
Corneal staining
Median (interquartile range) 3.0 (2.0–4.8) 3.0 (2.0–5.5) 1.5 (0.0–3.0) 0.030*
Corneal staining zones with staining grade[1 No. (%)
Superior 4 (16.7) 2 (11.8) 2 (8.3) 0.890
Inferior 10 (41.7) 6 (35.3) 6 (25.0) 0.47
Nasal 4 (16.7) 4 (23.5) 2 (8.3) 0.40
Temporal 3 (12.5) 5 (29.4) 2 (8.3) 0.16
Central 6 (25.0) 3 (17.6) 3 (12.5) 0.522
Number of MG plugs
Median (interquartile range) 27.0 (14.0–44.5) 37.0 (6.0–45.0) 22.5 (6.0–34.5) 0.331
Marx’s Line score
Mean ± SD 6.5 ± 3.4 5.5 ± 2.9 5.2 ± 2.9 0.672
Schirmer I/mm
Median (interquartile range) 7 (2–19) 9 (1–18) 12 (6–22) 0.329
IOP/mmHg
Mean ± SD 12.4 ± 2.4 13.1 ± 3.6 13.3 ± 3.0 0.539
Patients with viscous meibum
No. (%) 14 (58.3) 12 (70.6) 10 (41.7) 0.174
VA–log MAR
Median (interquartile range) 0.07 (0.01–0.23) 0.04 (0.00–0.14) 0.00 (0.00–0.18) 0.511
A smaller log MAR represents better acuity. Post hoc test for symptom severity: Towel vs EyeGiene, p\0.001; Blephasteam vs. EyeGiene,
p = 0.0228; Towel vs. Blephastem, p = 0.1233. Post hoc tests for corneal staining: EyeGiene vs. Blephasteam, * p = 0.0299; Towel vs.
Blephasteam, * p = 0.019; Towel vs Eyegiene, p = 0.6985
MG meibomian gland, No number of patients, SD standard deviation, TBUT tear break up time, VA visual acuity
*p\0.05
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differences at this 1-month treatment time
point.
At the last follow-up (3 months) in the study,
the proportions in each study arm with
improvement in the frequency of irritation
were; warm towel 50.0%, EyeGiene 41.2%
and Blephasteam 82.6%. The Blephasteam
arm had a significantly greater proportion with
improvement in the frequency compared to the
warm towel group (p = 0.020). The proportions
of patients with reduced severity of symptoms
were 45.5%, 41.2% and 78.3%, respectively.
Again the improvement was significantly
greater in the Blephasteam compared to the
towel group (p = 0.023).
Since EyeGiene gave similar results as warm
towel (Table 2), this report focused on the
logistic regression comparing Blephasteam
against warm towel (Table 3). The final logistic
regression model for improvement of symptom
severity after 1 month of treatment included
the variables of treatment (Blephasteam versus
warm towel) and age (Table 3). In this model,
Blephasteam is 5.67 (95% Confidence interval
[CI]: 1.30–24.66) times more efficacious than
warm towel. Older participants were slightly
more likely to have reduced symptom severity
after 1 month of treatment.
There was no significant difference among
the three groups for change in TBUT at 1 month
(p = 0.669; Table 4). After 3 months of
treatment, there was also no significant
difference in the change in TBUT (p = 0.612).
There was no significant change in Schirmers I,
Marx’s line score and meibum viscosity among
the participants at 3 months (data not shown).
Although there was a significant decrease in the
total number of plugged MG orifices (p\0.001)
over 12 weeks, there was no significant
difference among the three treatment groups
after 1 month (p = 0.656) and 3 months of
treatment (p = 0.926) (Table 5).
All three eyelid-warming methods did not
worsen participants’ VA after 3 months of twice-
daily treatment (p = 0.672, 0.769 and 0.900;
Supplementary Table 4). There were two reports
of unexpected AEs that were not related to
study treatment.

















1 month (n5 24)






13 (54.2) 9 (52.9) 0.938 19 (79.2) 0.066
Severity decreased after
1 month
12 (50.0) 9 (52.9) 0.853 18 (75.0) 0.074
Frequency decreased
after 3 months
11 (50.0) 7 (41.2) 0.584 19 (82.6) 0.020*
Severity decreased after
3 months
10 (45.5) 7 (41.2) 0.789 18 (78.3) 0.023*
No number of participants
*p\0.05
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DISCUSSION
At 1 month, all types of lid warming improved
symptoms by 50% or more. Blephasteam
relieved symptoms of eye discomfort for a
significantly greater proportion of participants
than warm towel up to 3 months of
treatment. In this study, EyeGiene did not
show any advantage over the warm towel but
this could be due to either a lower symptom
severity at baseline or reduced participation
related to technical difficulty of using the
device. All treatment modalities did not harm
vision.
Table 5 Change in number of plugged meibomian gland openings from baseline
From baseline to 1 month From baseline to 3 months
N Change in no. of
plugged MG openingsa
P value^ N Change in no. of
plugged MG openingsa
P value^
Towel 24 -2.5 (-9.5 to 0.5) 0.656 22 -7.5 (-18.0 to -3.0) 0.926
EyeGiene 17 -1.0 (-8.0 to 4.0) 17 -5.0 (-26.0 to 0.0)
Blephasteam 24 -2.0 (-5.5 to 1.0) 23 -7.0 (-13.0 to -4.0)
MG meibomian gland, N number of participants
^ As determined by Kruskal–Wallis equality-of-populations rank test
a Values are reported as median (interquartile range)
Table 3 Logistic regression models for improvement in severity of eye discomfort after 1 month of treatment
Variable Crude odds
ratio (95% CI)
P value Adjusteda odds
ratio (95% CI)
P value
Blephasteam treatment (vs. warm towel) 3.00 (0.88–10.18) 0.078 5.67 (1.30–24.66) 0.021*
Age 1.06 (1.00–1.12) 0.050 1.08 (1.02–1.16) 0.015*
n = 24 for Blephasteam and n = 24 for warm towel
CI conﬁdence interval of the odds ratio
*p\0.05
a Dependent variable was improvement of severity of discomfort. Covariates/independent variables were treatment and age
Table 4 Change in tear breakup time from baseline
From baseline to 1 month From baseline to 3 months
N Change in TBUTa P value^ N Change in TBUTa P value^
Towel 24 0.4 (-0.6 to 1.3) 0.669 22 0.2 (-0.4 to 1.9) 0.612
EyeGiene 17 0.4 (-0.2 to 0.9) 17 -0.1 (-0.5 to 1.6)
Blephasteam 24 0.5 (-0.1 to 2.2) 23 0.8 (-0.3 to 1.9)
Shorter TBUT implies a more unstable tear ﬁlm which is associated with dry eyes
N number of participants, TBUT tear breakup time
^ As determined by Kruskal–Wallis equality-of-populations rank test
a Values are reported as median (interquartile range) in seconds
44 Ophthalmol Ther (2014) 3:37–48
While the methods of assessing symptomatic
improvement and duration of study differ, three
previous studies are essentially in agreement
with our results that demonstrate Blephasteam
improved patients’ symptoms [17–19].
EyeGiene, which has also been marketed as
iHeat, relieved ocular symptoms in 56%
participants in a previous 2-week study [15].
This study showed similar results, with *50%
who improved after 1 month (Table 2) followed
by a slightly lower 41.2% between 1 and
3 months of treatment. This, however, was not
different than warm towel. Significant
improvement in VA after a one-time
Blephasteam treatment in healthy
participants [20] and dry eye patients has been
reported. This study, however, was interested in
the longer-term effect of heat therapy on the
eyes and showed no significant change of BCVA
in MGD participants after 3 months of therapy.
Villani et al. [17] reported significant
improvement in TBUT after 3 weeks of
Blephasteam treatment but Doan et al. [19]
disagreed. The majority of the Blephasteam
participants had increased TBUT after 1 and
3 months of treatment but this change in TBUT
was not significantly different compared to
warm towel or EyeGiene participants
(Table 4). There was no significant change in
TBUT in a 2-week study of EyeGiene treatment
[15]. Instead of looking at just the change in
TBUT with EyeGiene treatment, the authors
wanted to see if the change was different among
the three treatment groups but it was not
(Table 4). There were no reports on effect of
eyelid-warming therapy on plugging of MG
openings for comparison. Besides these studies
participants’ complaints of inability to use
EyeGiene, 2 cases (1.4%) of moderate ocular
burning and minor discomfort or pain were also
previously reported [15]. Four EyeGiene
participants also gave feedback of short (only
about 6 min) and inconsistent heat therapy. It
may be that tighter quality control is necessary
for EyeGiene before widespread use in MGD
patients.
The possible reason for the advantage of
Blephasteam over conventional warm towel is
the more consistent delivery of heat over the
time of application of the device. It is not clear
if the use of moist heat in the Blephasteam
device is advantageous over dry heat.
The strengths of this study are
randomization, its duration and the presence
of warm towel therapy for comparison. This is
also the first report on efficacy of Blephasteam
and EyeGiene in a predominantly Chinese
population and the results concur with those in
previous studies.
This study has several limitations. The
patients were recruited largely from a referral
clinic and may not always reflect the general
patients with MGD. The authors had an
unexpected number of withdrawals from the
EyeGiene group. The eight withdrawals from
the EyeGiene group had more severe
symptoms at baseline. To compensate for the
reduced participants, the authors included more
EyeGiene subjects in a non-randomized way
using exactly the same eligibility criteria, and
compared this group to the towel group. In this
additional analysis, the baseline global
irritation score was still significantly lesser in
the EyeGiene group compared to the control
group (Supplementary Table 2). The safety
assessment of the Eyegiene device may not
be robust enough given reduced patient
numbers analyzed.
Temperature for the towel was not specified
and thus might defer from previously published
studies. The study might not be generalizable to
all MGD patients because our patients were
predominantly Chinese. As participants could
not be blinded, there might be some placebo-
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like effect affecting the results of the study.
Factors not covered in this report, possibly
inflammation, meibum composition and MG
atrophy can be associated with symptom
improvement.
Besides understanding the factors predicting
for treatment success, it would also be valuable
to conduct pathological or imaging studies to
understand the physiological or anatomical
mechanism behind the recovery of MGD after
eyelid-warming therapies. This trial also
included the measurement of tear evaporation
as well as meibography and laboratory
investigations such as tear and meibum
lipidomics analyses which will be presented in
upcoming reports.
CONCLUSION
A high proportion of participants respond
symptomatically to lid warming.
Blephasteam is more efficacious than
conventional warm towel compress for at least
3 months of MGD therapy. Studies to
understand the predictors of treatment success
such as older age would be beneficial for
treatment recommendations.
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